Followers | 645 |
Posts | 10,606 |
Boards Moderated | 2 |
Alias Born | 03/07/2015 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes...nice! I communicated with the CEO earlier this year. She is ambitious, reliable, developed a great business model, follows up, even knows the fundamentals about the stock trading.
Sibannac Inc. (OTC: SNNC) Gaining Momentum: Karl Gottschalk's Wealth of Experience with Jeeter Propels Growth
https://www.benzinga.com/pressreleases/23/08/ab34125122/sibannac-inc-otc-snnc-gaining-momentum-karl-gottschalks-wealth-of-experience-with-jeeter-propels-
Cannatech companies are essentially tech companies that have entered the wellness space with the objective of making a major mark. One such company is Sibannac Inc. SNNC. The companies function as the digital extension for producers and supply them with innovative solutions that can help improve products, compliance at state as well as federal levels, and customer experiences.
The company seemed to have embarked on such a move on August 22 with the appointment of Karl Gottschalk as the Chief Executive Officer of Immersive Brand Concepts Inc., its Oklahoma-based subsidiary unit. Immersive is a progressive wellness firm that is involved in the distribution and design of a significant range of all-natural offerings. Its offerings are already impressive and are still expanding. Some of the products on offer include hangover prevention, kratom energy, and organic health and immunity.
The appointment of Gottschalk as the CEO of the subsidiary was a significant move from Sibannac, given his experience in the sector. Before taking up the new position, he had held a range of executive posts, and at each of those posts, he had brought excellent leadership skills that led to strong results. He had been the National Director of Jeeter/Dreamfields, and during his tenure, the company made significant progress.
Gottschalk had led the efforts for the reformulation of all the strains of the pre-roll offerings from the company. That move resulted in boosting the company’s output by 100%. Additionally, he had also been responsible for introducing automation, which not only led to a reduction in labor costs but also brought about an improvement in product quality.
However, that was not all. During his stint at Jeeter/Dreamfields, he also headed the efforts to implement vape cart manufacturing automation and led the efforts to update the active infusion methodologies during the course of his tenure. His time at Jeeter/Dreamfields also involved considerable growth in business and the assessment of more opportunities.
The Chief Executive Officer of Sibannac, David Mersky, spoke about the appointment as well. He noted that everyone at the company was thrilled at the appointment of Gottschalk as the new CEO of Immersive. He went on to commend Gottschalk for his varied skill sets across manufacturing and formulations, which placed him at the top levels of the alternative health and wellness industries.
During his time at Jeeter/Dreamfields, the Jeeter brand had climbed to the top position in the pre-roll space. It is the world’s biggest-selling pre-roll brand, and a report from June 2023 put things into perspective. Thanks to the leadership of Gottschalk, Jeeter became number one through some unique offerings. It not only offered premium pre-rolls, but the product was made available in different strains, sizes, and styles, which appealed to a large cohort of customers. The brand had also made headway with its offerings of disposable live resin pens and liquid diamond vape cartridges. In June 2023, it was revealed that in California alone, two million units of the company’s pre-rolls were smoked per month.
It had also been noted that the product was not the only reason why it had become number 1. The premium experience that the brand offered was also one of the reasons why it had become so popular.
The company managed to create a buzz around its brand through such promotions as celebrity endorsements, limited-time releases, and a ‘holiday’ known as ‘Jetterday’, which is celebrated on November 6 every year. On Wednesday, the company released a rare strain. All that progress happened under the stewardship of Gottschalk, and is now available to “Sibannac Inc. SNNC ” through their wholly owned subsidiary“Immersive Brand Concepts” where more innovations will be taking place and will be announced in the future.
Indeed, there seems to be dilution now:
Outstanding Shares 231,401,258 08/30/2023
Restricted 132,724,027 08/30/2023
Unrestricted 98,677,231 08/30/2023
that were just 100 shares...for a week now 99% of the shares are traded in the upper 4 cents! That should set the baseline :)
SODE: Quarterly report out...once again: 1) gross profit 2) no change in OS 3) no convertible debt...entry pps IMO
https://www.otcmarkets.com/otcapi/company/financial-report/379530/content
A single small retailer tries to do s.th. here LOL....totally under the radar BUT WHAT A POTENTIAL! Tiny preserved SS on top of that
Restricted 61,891,497 08/29/2023
Unrestricted 47,758,041 08/29/2023
Outstanding Shares 109,649,538 08/29/2023
Authorized Shares 300,000,000 08/29/2023
No trick, just treat: I'll explain...One of the products they will bring on the market (acquired rights and patent from DRNK) is NoHo Beverage...that has not been manufactured and distributed since 2015 (trademark https://www.trademarks411.com/marks/87307595-noho) BUT back then the revenue was over one million bucks and it was profitable.
Lots of tweets about snnc coming in...some from folks with thousands of followers...noone wants to sell, no dilution, business as to various products on the rise = climb on small volume until it breaks out past a dime
Also, a quarterly financial report just came out which looks great (no SS change in a year, increased revenue, basically no convertible debt)
https://www.otcmarkets.com/stock/PPJE/disclosure
Absolutely. I have 12M and think about adding. There is also a massive bid today of ~80M. Haven't seen that in quite a while!
I was happy to have been able to maintain classic view (the new format is awfull IMO). But from today on it seems every time I open IHUB it switches off the classic view. So 20 times a day I have to click on classic view. Is there any way to avoid that? tx Thilo
MSRM: an unbelievable opportunity....6M tradable shares only! 2 year pps high of $2.9......and NOW these updates!
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/22/2023
Restricted 32,527,735 08/22/2023
Unrestricted 5,958,025 08/22/2023
MSRM: 6M tradable shares only! 2 year pps high of $2.9......with recent developments and sector an unbelievable opportunity
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/22/2023
Restricted 32,527,735 08/22/2023
Unrestricted 5,958,025 08/22/2023
MSRM: 6M tradable shares only! 2 year pps high of $2.9......with recent developments and sector an unbelievable opportunity
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/22/2023
Restricted 32,527,735 08/22/2023
Unrestricted 5,958,025 08/22/2023
MSRM: with recent developments and sector an unbelievable opportunity
6M tradable shares only! 2 year pps high of $2.9
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/22/2023
Restricted 32,527,735 08/22/2023
Unrestricted 5,958,025 08/22/2023
MSRM: with recent developments and sector an unbelievable opportunity
6M tradable shares only! 2 year pps high of $2.9
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/22/2023
Restricted 32,527,735 08/22/2023
Unrestricted 5,958,025 08/22/2023
Mushrooms, Inc. (OTC: MSRM) Announces Diverse Business Development Team Assembled to Drive Company Growth.
ESTERO, Fla., Aug. 23, 2023 Mushrooms Inc. (OTC:MSRM) - Mushrooms Inc., proudly introduces its newly-formed Business Development Team, strategically assembled to harness the momentum generated by the company's new technology and Innovation lab development. Comprising accomplished professionals with diverse backgrounds, this team is poised to catapult Mushrooms Inc. into a new era of innovation and growth.
Dr. Reid Jilek's inclusion reflects Mushrooms Inc.'s commitment to synergizing academic prowess with industry innovation. Holding advanced degrees in medical, life sciences, and engineering, Dr. Jilek has published extensively in national and international scientific journals. He was both a Presidential Fellow and a White House Fellow Candidate. Dr. Jilek has developed in excess of 10,000 professional contacts worldwide in the healthcare industry and investment world. His leadership roles in private and public companies, combined with a network spanning the healthcare industry, establish him as a bridge between academia and business growth.
Alicia M. Fantozzi brings over two decades of international corporate and structured finance experience to the team. With a focused track record of driving growth and fostering strategic alliances, her appointment resonates with Mushrooms Inc.'s vision. Having held key roles in strategic initiatives, Alicia's extensive experience uniquely equips her to lead the team's efforts in expanding market presence and revenue streams.
Her role as Principal at ReGen establishes a seed-stage idea lab for biomimicry-based regenerative technologies for water and agriculture., with a concentrated focus on arranging financing, field trials and propagation of advanced innovation initiatives and evaluating complimentary environmental technologies for international sustainability initiatives, Food, Water & Natural Resource Security. Her background, strategic acumen, and commitment to sustainable business practices resonate with Mushrooms Inc.’s mission of revolutionizing the mushroom industry.
Dr. Hyder Khoja, is a leading figure in the life sciences field with over 22 years of expertise spanning drug discovery, developmental science, and policy innovation. Holding a Ph.D. in "Molecular Biology" from INP-ENSAT and post-doctoral training at Michigan State University, his education grounds his visionary approach. Dr. Khoja is a distinguished scientist and visionary in the psychedelic sector, who brings a profound focus to the team. Notably, he is personally committed to pioneering the resurrection of coma patients using psilocybin, adding a transformative dimension to Mushrooms Inc.'s initiatives in the psychedelic space. Dr. Khoja is senior lead scientist in the Company’s patent pending Mycelium thread project showcasing the vast background that he brings in support of diverse projects.
David Flores, CEO of PSYC Corporation which owns and operates Psychedelic Spotlight, an industry-leading media authority for the psychedelic sector, brings his visionary leadership to the team. His strategic thinking and experience in the psychedelic landscape perfectly aligns with Mushrooms Inc.'s aspirations for developing multiple facets of the Mushroom sector. His marketing expertise and industry knowledge is integral to the Company as it evolves.
"This enhanced Business Development Team represents a pivotal milestone for Mushrooms Inc.," said Donald Steinberg, Board Director of Mushrooms Inc. "As we make strides in the mushroom sector, our team's collective experience and expertise provide a robust foundation for innovation and growth."
"We are delighted to introduce our exceptional Business Development Team," said Kimberly Zawi Carlson, CEO of Mushrooms Inc. "I've had the privilege of collaborating with these amazing individuals over the past months and I feel that they will collectively bring to Mushrooms Inc what is needed to step forward. I'm honored to announce a formal collaboration with these remarkable and versatile professionals. This strategic step is a direct response to the increasing interest surrounding our patent-pending technology and the forthcoming revenue-generating innovation lab. Alicia Fantozzi, Dr. Reid Jilek, David Flores, and Dr. Hyder Khoja each possess a distinctive skill set that will play a pivotal role in steering our company's growth trajectory. Their combined expertise will propel us forward and better address the investor interest and potential collaborations as we navigate the exciting opportunities ahead."
About Mushrooms Inc. (MSRM)
Mushrooms Inc. is a publicly traded company on the OTC Markets with the stock symbol MSRM.
The vision for Mushrooms, Inc. is to support the growth of the mushroom industry through collaboration, innovation and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms, Inc. Our current focus is on the industrial application of Mycelium for the creation of carbon-neutral products for the building and health care industries as well as creating supplements based on the proven health benefits of mushrooms. Research and Development is the path to achieving great innovation, and the pioneers are the ones we look to for their fortitude and enduring dedication to the world of mycology. The working relationships we foster will result in scientifically proven products that advance the health of body, mind, and environment.
About Dr. Reid Jilek
Dr. Jilek has advanced degrees in both the medical, life science and engineering disciplines. He was both a Presidential Fellow and a White House Fellow Candidate. He has published over 40 papers in national and international peer--reviewed scientific journals.
After completing his National Library of Medicine Post-Doctoral developing computer and mathematical models for Malaria, he decided to utilize his medical and scientific background in a business development capacity by acting as a VP of Business Development for private and public companies and a research institute.
Dr. Jilek has developed in excess of 8,000 professional contacts worldwide in the healthcare industry and investment world, to include: therapeutics, diagnostics, vaccines, gene therapy, medical devices, preclinical and clinical contract research organizations, nutraceuticals, generics, telemedicine, botanical, and biotech products, as well as the venture capital and investment banking industries.
He was a founding member of Frederick Research Center and of Asia Pacific Alliance Company. He has served on the Board of Directors, Scientific or Medical Advisory Boards, or Advisory Boards for more than 40 private and public companies since 1990, in the US, Canada, Mexico, Japan, Taiwan, China, Portugal, Moscow, Israel and Germany. He has also served as the CEO of four companies.
About Alicia Fantozzi
Alicia M. Fantozzi brings over 25 years of extensive expertise in project management and corporate finance to the Mushrooms Inc. Business Development Team. As Principal at ReGen, she has pioneered a seed-stage idea lab focused on applied biophysics, igniting innovation in regenerative technologies within water and agriculture sectors. With a trail of accomplishments, Alicia held the position of Chief Financial Officer at Resonant Technologies Group, propelling companies specializing in physics-based technologies for health diagnostics, immunotherapy, frequency-enabled agriculture, and material sciences. As Principal at Strategic Advisory, her influence extended to cross-border financial transactions, enhancing internal data intelligence, cyber security, and risk management. She has a proven track record in tax-structured finance and private equity, originating multi-jurisdictional tax-optimized financings for corporations and high-net-worth individuals. Alicia's remarkable experience continues to drive Mushrooms Inc.'s growth in the mushroom and psychedelic sectors.
About Dr. Hyder Khoja
Dr. Khoja, with over 22 years in Functional and Psychedelic Medicine, is a leading voice in Drug discovery and Developmental Science. He's developed treatments for Non-Alcoholic fatty liver disease using “cannabinoids” and “capsaicin”, and partnered on a project extracting Chaga Mushrooms for cancer treatment. Moreover, he's explored the potential of lipids and “Beta-Carotene” from Algae and a cancer drug from “Keyhole Limpet Hemocyanin (KLH).”
He founded "Transcendent Life Sci and Emblem Nutraceuticals, Inc," focusing on “Coma Resurrection Therapy” and the therapeutic benefits of psychotropic compounds.
Dr. Khoja acquired his Ph.D. from INP-ENSAT in 2003, trained at Michigan State University, and later joined faculties like Virginia-Tech. His 2011 research on "Algae to Biofuels" was lauded by the FAO-United Nations.
As the founder of "Transcendent Life Sci and Emblem Nutraceuticals, Inc," his legacy resonates at the intersection of science and transformation.
About David Flores
David Flores brings a wealth of visionary leadership to Mushrooms Inc.'s Business Development Team. Guiding Psychedelic and Cannabis Convergence, David Flores, CEO of PSYC Corporation and its subsidiary, Spotlight Media Corporation, is at the forefront of the psychedelic and cannabis landscape. Over the past decade, David's career has traversed legal, finance, and public markets. Based in the San Gabriel Valley of California, he drives a multimedia empire including Psychedelic Spotlight, Technical 420, and On The Bids.
David's journey began in legal and financial sectors, culminating in his leadership role. Since July 2020, he has steered Psychedelic Spotlight and PSYC Corporation's strategic growth. A former co-owner of a public and investor relations firm in Las Vegas, NV, David built connections with emerging companies in green energy and cannabis. His financial acumen was shaped by roles at respected law firms, including Greenberg Glusker LLP and Wood Smith Henning & Berman LLP.
Beyond his professional pursuits, David is a proud member of the LGBTQ+ community. He resides in West Linn, OR, with his partner and Yorkshire terrier, reflecting a multifaceted and visionary perspective.
Greetings from Mushrooms Inc.
We're excited to share our latest news (detailed in the press release below).
This announcement shines a spotlight on our newly formed Business Development Team — the unsung heroes propelling Mushrooms Inc forward. Their expertise is instrumental in our growth, exploring investment avenues, and forging intricate partnerships. With our revenue generating Innovation lab at the front of our aims, their financial acumen and holistic business view are crucial for multifaceted success. While this introduces a few team members, several others work diligently behind the scenes. Their contributions are equally invaluable.
I invite you to delve deeper into the About profiles of Dr. Jilek, Alicia Fantozzi, Dr. Khoja, and David Flores. Their distinct capabilities merit further exploration.
Thank you for your continued support of Mushrooms Inc.
Mushrooms, Inc. (OTC: MSRM) Announces Diverse Business Development Team Assembled to Drive Company Growth.
ESTERO, Fla., Aug. 23, 2023 Mushrooms Inc. (OTC:MSRM) - Mushrooms Inc., proudly introduces its newly-formed Business Development Team, strategically assembled to harness the momentum generated by the company's new technology and Innovation lab development. Comprising accomplished professionals with diverse backgrounds, this team is poised to catapult Mushrooms Inc. into a new era of innovation and growth.
Dr. Reid Jilek's inclusion reflects Mushrooms Inc.'s commitment to synergizing academic prowess with industry innovation. Holding advanced degrees in medical, life sciences, and engineering, Dr. Jilek has published extensively in national and international scientific journals. He was both a Presidential Fellow and a White House Fellow Candidate. Dr. Jilek has developed in excess of 10,000 professional contacts worldwide in the healthcare industry and investment world. His leadership roles in private and public companies, combined with a network spanning the healthcare industry, establish him as a bridge between academia and business growth.
Alicia M. Fantozzi brings over two decades of international corporate and structured finance experience to the team. With a focused track record of driving growth and fostering strategic alliances, her appointment resonates with Mushrooms Inc.'s vision. Having held key roles in strategic initiatives, Alicia's extensive experience uniquely equips her to lead the team's efforts in expanding market presence and revenue streams.
Her role as Principal at ReGen establishes a seed-stage idea lab for biomimicry-based regenerative technologies for water and agriculture., with a concentrated focus on arranging financing, field trials and propagation of advanced innovation initiatives and evaluating complimentary environmental technologies for international sustainability initiatives, Food, Water & Natural Resource Security. Her background, strategic acumen, and commitment to sustainable business practices resonate with Mushrooms Inc.’s mission of revolutionizing the mushroom industry.
Dr. Hyder Khoja, is a leading figure in the life sciences field with over 22 years of expertise spanning drug discovery, developmental science, and policy innovation. Holding a Ph.D. in "Molecular Biology" from INP-ENSAT and post-doctoral training at Michigan State University, his education grounds his visionary approach. Dr. Khoja is a distinguished scientist and visionary in the psychedelic sector, who brings a profound focus to the team. Notably, he is personally committed to pioneering the resurrection of coma patients using psilocybin, adding a transformative dimension to Mushrooms Inc.'s initiatives in the psychedelic space. Dr. Khoja is senior lead scientist in the Company’s patent pending Mycelium thread project showcasing the vast background that he brings in support of diverse projects.
David Flores, CEO of PSYC Corporation which owns and operates Psychedelic Spotlight, an industry-leading media authority for the psychedelic sector, brings his visionary leadership to the team. His strategic thinking and experience in the psychedelic landscape perfectly aligns with Mushrooms Inc.'s aspirations for developing multiple facets of the Mushroom sector. His marketing expertise and industry knowledge is integral to the Company as it evolves.
"This enhanced Business Development Team represents a pivotal milestone for Mushrooms Inc.," said Donald Steinberg, Board Director of Mushrooms Inc. "As we make strides in the mushroom sector, our team's collective experience and expertise provide a robust foundation for innovation and growth."
"We are delighted to introduce our exceptional Business Development Team," said Kimberly Zawi Carlson, CEO of Mushrooms Inc. "I've had the privilege of collaborating with these amazing individuals over the past months and I feel that they will collectively bring to Mushrooms Inc what is needed to step forward. I'm honored to announce a formal collaboration with these remarkable and versatile professionals. This strategic step is a direct response to the increasing interest surrounding our patent-pending technology and the forthcoming revenue-generating innovation lab. Alicia Fantozzi, Dr. Reid Jilek, David Flores, and Dr. Hyder Khoja each possess a distinctive skill set that will play a pivotal role in steering our company's growth trajectory. Their combined expertise will propel us forward and better address the investor interest and potential collaborations as we navigate the exciting opportunities ahead."
About Mushrooms Inc. (MSRM)
Mushrooms Inc. is a publicly traded company on the OTC Markets with the stock symbol MSRM.
The vision for Mushrooms, Inc. is to support the growth of the mushroom industry through collaboration, innovation and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms, Inc. Our current focus is on the industrial application of Mycelium for the creation of carbon-neutral products for the building and health care industries as well as creating supplements based on the proven health benefits of mushrooms. Research and Development is the path to achieving great innovation, and the pioneers are the ones we look to for their fortitude and enduring dedication to the world of mycology. The working relationships we foster will result in scientifically proven products that advance the health of body, mind, and environment.
About Dr. Reid Jilek
Dr. Jilek has advanced degrees in both the medical, life science and engineering disciplines. He was both a Presidential Fellow and a White House Fellow Candidate. He has published over 40 papers in national and international peer--reviewed scientific journals.
After completing his National Library of Medicine Post-Doctoral developing computer and mathematical models for Malaria, he decided to utilize his medical and scientific background in a business development capacity by acting as a VP of Business Development for private and public companies and a research institute.
Dr. Jilek has developed in excess of 8,000 professional contacts worldwide in the healthcare industry and investment world, to include: therapeutics, diagnostics, vaccines, gene therapy, medical devices, preclinical and clinical contract research organizations, nutraceuticals, generics, telemedicine, botanical, and biotech products, as well as the venture capital and investment banking industries.
He was a founding member of Frederick Research Center and of Asia Pacific Alliance Company. He has served on the Board of Directors, Scientific or Medical Advisory Boards, or Advisory Boards for more than 40 private and public companies since 1990, in the US, Canada, Mexico, Japan, Taiwan, China, Portugal, Moscow, Israel and Germany. He has also served as the CEO of four companies.
About Alicia Fantozzi
Alicia M. Fantozzi brings over 25 years of extensive expertise in project management and corporate finance to the Mushrooms Inc. Business Development Team. As Principal at ReGen, she has pioneered a seed-stage idea lab focused on applied biophysics, igniting innovation in regenerative technologies within water and agriculture sectors. With a trail of accomplishments, Alicia held the position of Chief Financial Officer at Resonant Technologies Group, propelling companies specializing in physics-based technologies for health diagnostics, immunotherapy, frequency-enabled agriculture, and material sciences. As Principal at Strategic Advisory, her influence extended to cross-border financial transactions, enhancing internal data intelligence, cyber security, and risk management. She has a proven track record in tax-structured finance and private equity, originating multi-jurisdictional tax-optimized financings for corporations and high-net-worth individuals. Alicia's remarkable experience continues to drive Mushrooms Inc.'s growth in the mushroom and psychedelic sectors.
About Dr. Hyder Khoja
Dr. Khoja, with over 22 years in Functional and Psychedelic Medicine, is a leading voice in Drug discovery and Developmental Science. He's developed treatments for Non-Alcoholic fatty liver disease using “cannabinoids” and “capsaicin”, and partnered on a project extracting Chaga Mushrooms for cancer treatment. Moreover, he's explored the potential of lipids and “Beta-Carotene” from Algae and a cancer drug from “Keyhole Limpet Hemocyanin (KLH).”
He founded "Transcendent Life Sci and Emblem Nutraceuticals, Inc," focusing on “Coma Resurrection Therapy” and the therapeutic benefits of psychotropic compounds.
Dr. Khoja acquired his Ph.D. from INP-ENSAT in 2003, trained at Michigan State University, and later joined faculties like Virginia-Tech. His 2011 research on "Algae to Biofuels" was lauded by the FAO-United Nations.
As the founder of "Transcendent Life Sci and Emblem Nutraceuticals, Inc," his legacy resonates at the intersection of science and transformation.
About David Flores
David Flores brings a wealth of visionary leadership to Mushrooms Inc.'s Business Development Team. Guiding Psychedelic and Cannabis Convergence, David Flores, CEO of PSYC Corporation and its subsidiary, Spotlight Media Corporation, is at the forefront of the psychedelic and cannabis landscape. Over the past decade, David's career has traversed legal, finance, and public markets. Based in the San Gabriel Valley of California, he drives a multimedia empire including Psychedelic Spotlight, Technical 420, and On The Bids.
David's journey began in legal and financial sectors, culminating in his leadership role. Since July 2020, he has steered Psychedelic Spotlight and PSYC Corporation's strategic growth. A former co-owner of a public and investor relations firm in Las Vegas, NV, David built connections with emerging companies in green energy and cannabis. His financial acumen was shaped by roles at respected law firms, including Greenberg Glusker LLP and Wood Smith Henning & Berman LLP.
Beyond his professional pursuits, David is a proud member of the LGBTQ+ community. He resides in West Linn, OR, with his partner and Yorkshire terrier, reflecting a multifaceted and visionary perspective.
Prior Press Releases
Poised for Textile Innovation and Global Impact as Full Patent Filing for Mycelium Thread Nears Completion
CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast
Announces Plan for Acquisitions and Vertically Integrated Business Development by Partnering with diversified Mushroom Market Leaders
Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC Markets to “MSRM”
I can't recall -- when the CEO in the podcast mentioned updates coming in august was that to the just released patent news...or already updates to acquisitions? Either way lets see what the next three months bring...so far she has followed the business layout like a clockwork
6M tradable shares only! 2 year pps high of $2.9
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/22/2023
Restricted 32,527,735 08/22/2023
Unrestricted 5,958,025 08/22/2023
absolutely...golden cross ~0.048 !!!!
After zero last quarter now revenue and gross profit again. SS still the same and NO CONVERTIBLE NOTES whatshowever. Insiders holding almost half of the common shares. This can go to pennies as before....mark my words. https://www.otcmarkets.com/otcapi/company/financial-report/379728/content
Listen to the recent interview featuring MSRM CEO Kimberly Carlson (where she addresses preserving the share structure and not taking convertible debt) https://psychedelicspotlight.com/using-mycelium-for-a-sustainable-future-feat-kimberly-carlson/
One of the products they will bring on the market (acquired rights and patent from DRNK) is NoHo Beverage...that has not been manufactured and distributed since 2015 (trademark https://www.trademarks411.com/marks/87307595-noho) BUT back then the revenue was over one million bucks and it was profitable.
They exist, are at bottom pps, never dilute, have small SS, file in time....these are the ingredients for better reward/risk ratio than with most OTC stocks. All we need are runs in pps, not necessarily flourishing business.
SKPO has no convertible notes, minimal OS, the SS has not changed in many years:
Market Cap 712,384
Authorized Shares 290,000,000 08/16/2023
Outstanding Shares 249,959,400 08/16/2023
Restricted 138,532,272 08/18/2023
Unrestricted 111,427,128 08/16/2023
Held at DTC 70,384,931 08/16/2023
SKPO's comprehensive list of products (recently updated). They hold a high number of patents incl. for these products:
SKPO has no convertible notes, minimal OS, the SS has not changed in many years:
Market Cap 712,384
Authorized Shares 290,000,000 08/16/2023
Outstanding Shares 249,959,400 08/16/2023
Restricted 138,532,272 08/18/2023
Unrestricted 111,427,128 08/16/2023
Held at DTC 70,384,931 08/16/2023
Dispersants
Skye Chem WD-C (Wax Dispersant - Concentrate)
Wax Dispersant, emulsion breaker, sludge dispersant, viscosity reducer.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/WD-C%20%20TDS%20concentrate%20for%20wax.pdf?ver=1564971876336
Skye Chem AD-C (Asphaltene Dispersant - Concentrate) Ready to Use)
An aqueous proprietary blend of a unique phosphonate and high performance Acrylate Co-polymer. It is used to control the formation of calcium scale and metal oxides in a wide variety of oilfield and industrial formations and applications.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/AD-C%20%20TDS%20concentrate%20for%20asphaltene.pdf?ver=1564971876335
Skye chem WD-RTU
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/SDS%20Skye%20WD-RTU%20-%202016%20January.pdf?ver=1649632935616
Solvents
Skye Chem WD-RTU (Wax Dispersant - Ready to Use)
Solvent surfactant combination for the removal of wax deposits from production strings, formations, pipelines, and vessels.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/WD-RTU%20-%20TDS%20ready%20to%20use%20field%20strength%20for%20w.pdf?ver=1564971510465
Skye Chem AD-RTU (Asphaltene Dispersant - Ready to Use)
Solvent surfactant combination for the removal or asphaltenic deposits from production strings, formations, pipelines, and vessels.
Skye Chem Sludge Buster
A blend of solvents and surfactants designed to disperse hydrocarbon sludges containing a mix of waxes and asphaltenes.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20Sludge%20Buster%20-%20TDS.pdf?ver=1564971510465
Wax Inhibitors
Skye Chem X-110
High molecular weight crystal modifier and dispersant combination. Excellent for high melting point waxes and wax appearance temperature between 30 - 50 C.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-110%20TDS_v6.14.pdf?ver=1564971876336
Skye Chem X-112
Polyalkylated phenol - pour point depressant and wax dispersant. Modified to have better cold temperature performance and effective on both microcrystalline wax and intermediate wax appearance temperatures.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-112%20TDS_v6.14.pdf?ver=1564971876336
Skye Chem X-115
Very high molecular weight inhibitor for waxes with a melting point range above 60C.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-115%20TDS_v6.14.pdf?ver=1564971876336
Skye Chem X-125
A medium molecular weight copolymer ester based pour point depressant. Designed for pour point ranges between 20 and 35C.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-125%20TDS_v6.14.pdf?ver=1564971876336
Skye Chem X-126
An oil soluble wax crystal modifier intended to reduce pour points, modify oil viscosity and change the wax appearance temperature (WAT) or wax crudes with WAT in the range of 10 - 25C. (50 - 80F)
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-126%20TDS_v6.14.pdf?ver=1564971876336
Summary:
Skye Petroleum, Inc. located in Sugar Land, Texas, offers production chemical treatment services to oil companies that battle flow assurance issues relating to paraffin, asphaltene and sludge. The Company also offers a significant line of Drilling and Completion fluids, as well as a concentrated degreaser agent that has performed extremely well against the competition.
The Production Chemistries, which were developed over several years and sold under the Skye Chem name, are unique as they perform powerfully in many different regions. Skye has reported successful results in suspending paraffin, asphaltene and sludge in many of the major oil producing states in the US; such as, Texas (Permian Basin and Eagle Ford Shale Formations), North Dakota and Pennsylvania, in addition to many other locations. Once the paraffin wax has been returned to liquid form, it will remain in that state all the way to the refinery.
Lab testing has also shown the chemistry to be effective against paraffin wax in other parts of the world. Due to these results, Skye is seeking partners to expand internationally into significant oil producing countries. Skye’s chemistries are effective in oil wells, flowlines, storage tanks, pipelines, vessels, railcars, terminals and refineries.
The chemistry was designed to be effective on a wide range of paraffin waxes and to work quickly. Larry Gatlin, a seasoned veteran in oilfield chemistry, stated that the Skye Chem Wax Dispersant (WD-RTU) chemical is the fastest acting paraffin dispersant he has seen, on the widest number of paraffin samples. Skye Petroleum, Inc. is a publicly traded corporation listed on the OTCMarkets “Current Information” Tier.
Always filing in time https://www.otcmarkets.com/stock/SKPO/disclosure
Last quarterly report just out!
Quarterly report out (in time as usual)https://www.otcmarkets.com/otcapi/company/financial-report/379057/content
Quarterly report is out. This is a true merger (see new insider/CEO/CFO/institutional related holdings) for big buisiness. Needs to, and should, play out soon.
https://www.otcmarkets.com/stock/GBHL/disclosure
CRSM: Float 175M; OS unchanged for 3 years; filings regular (gross profits for the last nine quarters)
No Promissory Notes or Convertible Debt
Outstanding Shares 595,304,566 06/30/2023
Outstanding Shares 595,304,566 11/12/2021
https://www.otcmarkets.com/otcapi/company/financial-report/378552/content
Director/CFO holds 310M common shares without ever selling even one!
Outstanding Shares 1,265,434,915 08/13/2023
Restricted 32,345,325 08/13/2023
Unrestricted 1,233,089,590 08/13/2023
They are on top of it...hopefully, revenues after recent merger show up for Q2. 08/14/2023 Notification of Late Filing - Notification Late Filing Q2
financials out! No SS change in a year https://www.otcmarkets.com/stock/PPJE/disclosure